We’ve rebranded some of our products, learn more ›
Original Air Date: July 27, 2022
Tertiary lymphoid structures (TLS) are lymph node-like organisations of immune cells within inflamed tissues that can drive immune cell activation. Solid tumours exhibit TLS development, which is associated with improved survival of untreated patients. Similarly, in patients treated with immune checkpoint inhibitors, TLS development is often associated with improved therapeutic response. This has prompted the hypothesis that TLS are sites where antitumor immunity is generated. For this webinar, the speaker will introduce what is already known about TLS, what the main open questions are, and what analysis approaches can be used to understand the biology of tumor-associated TLS.
In this webinar Dr. Silina will introduce what is already known about tertiary lymphoid structures (TLS), what the main open questions are, and what analysis approaches can be used to understand the biology of tumor-associated TLS.
In this Webinar You Will:
Dr. Silina is a Swiss National Science Foundation (SNSF) PRIMA group leader at the Institute of Pharmaceutical Sciences (IPW) at the ETH Zurich. She obtained her Ph.D. from the University of Latvia, Faculty of Biochemistry and Molecular Biology, studying autoantibody responses in cancer patients. She then continued her research at the Latvian Biomedical Research and Study Centre, developing a potential diagnostic tool for early tumor diagnosis using serum autoantibodies. She then joined the laboratory of Maries van den Broek at the Institute of Experimental Immunology, University of Zurich. In 2021, Dr. Silina started her own laboratory at the IPW, where her ongoing research efforts aim to define the physiological role and mechanisms of tertiary lymphoid structure (TLS) development in cancer, which could potentially be used for deliberate TLS induction as a novel immunotherapeutic approach.
Sign up to receive our eNewsletter, new product updates, events, and more!